UY28783A1 - Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona - Google Patents

Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona

Info

Publication number
UY28783A1
UY28783A1 UY28783A UY28783A UY28783A1 UY 28783 A1 UY28783 A1 UY 28783A1 UY 28783 A UY28783 A UY 28783A UY 28783 A UY28783 A UY 28783A UY 28783 A1 UY28783 A1 UY 28783A1
Authority
UY
Uruguay
Prior art keywords
piridacin
ona
benzimidazol
compounds
new derivatives
Prior art date
Application number
UY28783A
Other languages
English (en)
Inventor
Hoelder Swen
Schoenafinger Karl
Will David William
Matter Hans
Mueller Guenther
Combeau Cecile
Delaisi Christine
Steinmetz Anke
Sassoon Ingrid
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY28783A1 publication Critical patent/UY28783A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invención se refiere a compuestos de la fórmula general (I), detallándose la definición de los sustituyentes A, B, D, E, R1 y R2 en la descripción, y las sales fisiológicamente toleradas de los mismos, a un proceso para la preparación de estos compuestos y a su uso como productos farmacéuticos. Estos compuestos son inhibidores de quinasa, en particular inhibidores de la quinasa CDK2 (quinasa 2 dependiente de ciclina).
UY28783A 2004-03-02 2005-03-02 Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona UY28783A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004010207A DE102004010207A1 (de) 2004-03-02 2004-03-02 Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate

Publications (1)

Publication Number Publication Date
UY28783A1 true UY28783A1 (es) 2005-09-30

Family

ID=34853913

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28783A UY28783A1 (es) 2004-03-02 2005-03-02 Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona

Country Status (14)

Country Link
US (2) US7470689B2 (es)
EP (1) EP1723137A1 (es)
JP (1) JP4792455B2 (es)
KR (1) KR20070008582A (es)
CN (1) CN101061108A (es)
AR (1) AR047987A1 (es)
AU (1) AU2005219563A1 (es)
BR (1) BRPI0508364A (es)
CA (1) CA2555161A1 (es)
DE (1) DE102004010207A1 (es)
IL (1) IL177204A0 (es)
TW (1) TW200538452A (es)
UY (1) UY28783A1 (es)
WO (1) WO2005085231A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP2298770A1 (en) * 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
MX2009000884A (es) * 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
BRPI1107312B1 (pt) 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324580A1 (de) 1993-07-22 1995-01-26 Thomae Gmbh Dr K Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
TR200103806T2 (tr) * 1999-06-28 2002-06-21 Janssen Pharmaceutica N. V. Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
KR20030083016A (ko) * 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 신규 타이로신 카이나제 억제제
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
EP1413578A4 (en) 2001-07-27 2004-10-20 Yamanouchi Pharma Co Ltd NEW CRYSTAL OF AN ARYLETHEN SULPHONAMIDE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20040142932A1 (en) 2002-01-18 2004-07-22 Michael Hepperle Substituted pyridazinones
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
MXPA04008364A (es) 2002-02-28 2005-07-26 Sanofi Aventis Derivados de 2-piridinil y 2-pirimidinil-6, 7, 8, 9-tetrahidropirmido [1,2-a] pirimidin-4-ona substituidos por heteroarilo.
HU227255B1 (en) * 2002-04-26 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
AU2003240517A1 (en) 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
EP1572200B1 (fr) 2002-12-12 2011-08-17 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
IL157751A0 (en) 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
KR20050113627A (ko) * 2003-03-18 2005-12-02 코와 가부시키가이샤 수용성 페닐피리다진 유도체 및 이를 함유하는 의약
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
US7232939B2 (en) 2004-05-28 2007-06-19 E.I. Du Pont De Nemours And Company Nucleic acid molecules encoding cyclotide polypeptides and methods of use
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates

Also Published As

Publication number Publication date
US7754713B2 (en) 2010-07-13
AR047987A1 (es) 2006-03-15
AU2005219563A1 (en) 2005-09-15
TW200538452A (en) 2005-12-01
JP2007531712A (ja) 2007-11-08
US20070173503A1 (en) 2007-07-26
EP1723137A1 (en) 2006-11-22
KR20070008582A (ko) 2007-01-17
CA2555161A1 (en) 2005-09-15
US7470689B2 (en) 2008-12-30
US20090042880A1 (en) 2009-02-12
DE102004010207A1 (de) 2005-09-15
IL177204A0 (en) 2006-12-10
BRPI0508364A (pt) 2007-07-24
WO2005085231A1 (en) 2005-09-15
CN101061108A (zh) 2007-10-24
JP4792455B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
UY28783A1 (es) Nuevos derivados de 4-benzimidazol-2-il-piridacin-3-ona
UY28903A1 (es) Nuevos derivados de piridazinona
UY28902A1 (es) Derivados de piridazinona, métodos para producirlos y su uso como productos farmacéuticos
NI200900076A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso.
ECSP077271A (es) Derivados de pirimidina
ECSP077259A (es) Derivados de pirimidina
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
UY29039A1 (es) Nuevos derivados amino de urea cíclicos, su preparación y su uso farmacéutico como inhibidores de quinasa
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
UY30327A1 (es) Nuevos compuestos ii
UY28745A1 (es) Nuevos compuestos
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
HN2010000653A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120418